According to a study presented at the 76th Scientific Sessions of the ADA and published in The New England Journal of Medicine, pioglitazone showed its efficacy in reducing the risk of type 2 diabetes by 52% in non-diabetic (especially individuals with pre-diabetes), insulin-resistant people with Cerebrovascular disease. The investigators stated that pioglitazone appears to be …
Monthly Archive: June 2016
Jun 28
Impact of alogliptin therapy on cardiovascular events in type 2 diabetes
The researchers conducted a post-hoc analysis of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial which revealed that the use of alogliptin, a dipeptidyl peptidase-4 inhibitor was not associated with cardiovascular-related mortality in patients with type 2 diabetes mellitus who experienced acute coronary syndrome. In addition, it did not cause …
Jun 21
Lower BP goals are better for elderly
Among ambulatory adults aged 75 years or older, treating to a systolic blood pressure target of less than 120 mm Hg (intensive control) compared with a systolic blood pressure target of less than 140 mm Hg (standard control) resulted in 34% relatively lower risk of fatal and nonfatal major cardiovascular events and death from cardiovascular …
Jun 20
High consumption of sugar-sweetened carbonated beverages associated with increased CAC
Results of a large cross-sectional study of 22,210 asymptomatic men and women published in the July 2016 issue of the American Heart Journal show that high levels of sugar-sweetened carbonated beverage consumption are associated with a higher prevalence and degree of coronary artery calcium (CAC) in asymptomatic adults without a history of cardiovascular disease, cancer, …
Jun 17
Diastolic orthostatic HT associated with decreased risk for incident cardiovascular events
According to a prospective cohort study published June 2, 2016 in the journal Cardiovascular Diabetology, diastolic orthostatic hypertension (HT) is common in patients with type 2 diabetes, and may be a novel marker for decreased cardiovascular risk in these patients. Diastolic orthostatic hypotension was found in 4.1 % in the study and it was associated …
Jun 14
Cardiovascular mortality is higher in patients with type 2 diabetes and recent ACS
A post hoc analysis of the Examination of Cardiovascular Outcomes With Alogliptin versus Standard of Care (EXAMINE) trial with the type 2 diabetes drug alogliptin (Nesina, Takeda), an oral dipeptidyl peptidase–4 (DPP-4) inhibitor, has shown that the risk of cardiovascular death was higher if patients in the trial had first experienced a nonfatal cardiovascular event, …
Jun 13
Early removal of Nanostim leadless pacemaker is safe
A new research presented June 8, 2016 at the recent European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2016 meeting in Nice, France has shown that it is feasible and safe to remove the Nanostim leadless pacemaker (St Jude Medical) up to 3.2 years after implantation. The procedural success rate was 93.3% among 15 patients who underwent …
Jun 13
Early removal of Nanostim leadless pacemaker is safe
A new research presented June 8, 2016 at the recent European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2016 meeting in Nice, France has shown that it is feasible and safe to remove the Nanostim leadless pacemaker (St Jude Medical) up to 3.2 years after implantation. The procedural success rate was 93.3% among 15 patients who underwent …
Jun 12
Study links long-term rise in hs-cTnT to coronary heart disease, HF and all-cause mortality
Temporal increases in high-sensitivity cardiac troponin T (hs-cTnT), suggestive of progressive myocardial damage, are independently associated with incident coronary heart disease, death, and, above all, heart failure (HF). Based on the results, a prospective observational cohort study published online June 8, 2016 suggests that serial determination of hs-cTnT trajectory adds clinically relevant information to baseline …
Jun 11
High plasma endothelin-1 associated with pulmonary HT and mortality risk
Raised plasma endothelin-1 levels, especially associated with an elevated pulmonary artery systolic pressure on echocardiogram, may identify an at-risk population that could be evaluated for targeted prevention and management strategies. In an analysis of data from the ongoing Jackson Heart Study in JAMA Cardiology, published online June 8, 2016, African American participants with both pulmonary …
